-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UTbAaA1FeFedD3A4H4ohSLFfL8roiCj2aqQ6SDtgXZm90eRYWrXwh3mw3R4ejck8 t2tHkifEK64cRBxwi5fvJA== 0000950128-02-000213.txt : 20020414 0000950128-02-000213.hdr.sgml : 20020414 ACCESSION NUMBER: 0000950128-02-000213 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020212 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000910267 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49554 FILM NUMBER: 02536764 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 4152444990 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PNC FINANCIAL SERVICES GROUP INC CENTRAL INDEX KEY: 0000713676 STANDARD INDUSTRIAL CLASSIFICATION: NATIONAL COMMERCIAL BANKS [6021] IRS NUMBER: 251435979 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ONE PNC PLAZA STREET 2: 249 FIFTH AVE CITY: PITTSBURGH STATE: PA ZIP: 15265 BUSINESS PHONE: 4127621553 MAIL ADDRESS: STREET 1: ONE PNC PLAZA STREET 2: FIFTH AVENUE & WOOD STREET CITY: PITTSBURGH STATE: PA ZIP: 15265 FORMER COMPANY: FORMER CONFORMED NAME: PNC BANK CORP DATE OF NAME CHANGE: 19930505 FORMER COMPANY: FORMER CONFORMED NAME: PNC BANK CORP /PA/ DATE OF NAME CHANGE: 19930428 FORMER COMPANY: FORMER CONFORMED NAME: PNC FINANCIAL CORP /PA/ DATE OF NAME CHANGE: 19930412 SC 13G/A 1 j92672a9sc13ga.txt TITAN PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- SCHEDULE 13G (RULE 13D-102) INFORMATION STATEMENT PURSUANT TO RULE 13D-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (FINAL AMENDMENT) TITAN PHARMACEUTICALS, INC. --------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 888314101 --------- (CUSIP Number) December 31, 2001 ----------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 888314101 Page 1 of 7 Pages 1) Names of Reporting Persons IRS Identification No. Of Above Persons The PNC Financial Services Group, Inc. 25-1435979 2) Check the Appropriate Box if a Member of a Group (See Instructions) a) [ ] b) [ ] 3) SEC USE ONLY 4) Citizenship or Place of Organization Pennsylvania Number of Shares 5) Sole Voting Power * *See the response to Item 5. Beneficially Owned 6) Shared Voting Power * *See the response to Item 5. By Each Reporting 7) Sole Dispositive Power * *See the response to Item 5. Person With 8) Shared Dispositive Power * *See the response to Item 5. 9) Aggregate Amount Beneficially Owned by Each Reporting Person * *See the response to Item 5. 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares See Instructions [ ] 11) Percent of Class Represented by Amount in Row (9) * *See the response to Item 5. 12) Type of Reporting Person (See Instructions) HC SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- SCHEDULE 13G (RULE 13D-102) INFORMATION STATEMENT PURSUANT TO RULE 13D-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (FINAL AMENDMENT) TITAN PHARMACEUTICALS, INC. --------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 888314101 --------- (CUSIP Number) December 31, 2001 ----------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 888314101 Page 2 of 7 Pages 1) Names of Reporting Persons IRS Identification No. Of Above Persons PNC Bancorp, Inc. 51-0326854 2) Check the Appropriate Box if a Member of a Group (See Instructions) a) [ ] b) [ ] 3) SEC USE ONLY 4) Citizenship or Place of Organization Delaware Number of Shares 5) Sole Voting Power * *See the response to Item 5. Beneficially Owned 6) Shared Voting Power * *See the response to Item 5. By Each Reporting 7) Sole Dispositive Power * *See the response to Item 5. Person With 8) Shared Dispositive Power * *See the response to Item 5. 9) Aggregate Amount Beneficially Owned by Each Reporting Person * *See the response to Item 5. 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares See Instructions [ ] 11) Percent of Class Represented by Amount in Row (9) * *See the response to Item 5. 12) Type of Reporting Person (See Instructions) HC SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- SCHEDULE 13G (RULE 13D-102) INFORMATION STATEMENT PURSUANT TO RULE 13D-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (FINAL AMENDMENT) TITAN PHARMACEUTICALS, INC. --------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 888314101 --------- (CUSIP Number) December 31, 2001 ----------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 888314101 Page 3 of 7 Pages 1) Names of Reporting Persons IRS Identification No. Of Above Persons PNC Bank, National Association 22-1146430 2) Check the Appropriate Box if a Member of a Group (See Instructions) a) [ ] b) [ ] 3) SEC USE ONLY 4) Citizenship or Place of Organization United States Number of Shares 5) Sole Voting Power * *See the response to Item 5. Beneficially Owned 6) Shared Voting Power * *See the response to Item 5. By Each Reporting 7) Sole Dispositive Power * *See the response to Item 5. Person With 8) Shared Dispositive Power * *See the response to Item 5. 9) Aggregate Amount Beneficially Owned by Each Reporting Person * *See the response to Item 5. 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares See Instructions [ ] 11) Percent of Class Represented by Amount in Row (9) * *See the response to Item 5. 12) Type of Reporting Person (See Instructions) BK SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- SCHEDULE 13G (RULE 13D-102) INFORMATION STATEMENT PURSUANT TO RULE 13D-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (FINAL AMENDMENT) TITAN PHARMACEUTICALS, INC. --------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 888314101 --------- (CUSIP Number) December 31, 2001 ----------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 888314101 Page 4 of 7 Pages 1) Names of Reporting Persons IRS Identification No. Of Above Persons BlackRock Advisors, Inc. 23-2784752 2) Check the Appropriate Box if a Member of a Group (See Instructions) a) [ ] b) [ ] 3) SEC USE ONLY 4) Citizenship or Place of Organization Delaware Number of Shares 5) Sole Voting Power * *See the response to Item 5. Beneficially Owned 6) Shared Voting Power * *See the response to Item 5. By Each Reporting 7) Sole Dispositive Power * *See the response to Item 5. Person With 8) Shared Dispositive Power * *See the response to Item 5. 9) Aggregate Amount Beneficially Owned by Each Reporting Person * *See the response to Item 5. 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares See Instructions [ ] 11) Percent of Class Represented by Amount in Row (9) * *See the response to Item 5. 12) Type of Reporting Person (See Instructions) IA SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------- SCHEDULE 13G (RULE 13D-102) INFORMATION STATEMENT PURSUANT TO RULE 13D-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (FINAL AMENDMENT) TITAN PHARMACEUTICALS, INC. --------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 888314101 --------- (CUSIP Number) December 31, 2001 ----------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 888314101 Page 5 of 7 Pages 1) Names of Reporting Persons IRS Identification No. Of Above Persons BlackRock Financial Management, Inc. 13-3806691 2) Check the Appropriate Box if a Member of a Group (See Instructions) a) [ ] b) [ ] 3) SEC USE ONLY 4) Citizenship or Place of Organization Delaware Number of Shares 5) Sole Voting Power * *See the response to Item 5. Beneficially Owned 6) Shared Voting Power * *See the response to Item 5. By Each Reporting 7) Sole Dispositive Power * *See the response to Item 5. Person With 8) Shared Dispositive Power * *See the response to Item 5. 9) Aggregate Amount Beneficially Owned by Each Reporting Person * *See the response to Item 5. 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares See Instructions [ ] 11) Percent of Class Represented by Amount in Row (9) * *See the response to Item 5. 12) Type of Reporting Person (See Instructions) IA Page 6 of 7 Pages ITEM 5 - OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: Each reporting person has ceased to own beneficially more than 5% of the stock of the issuer. ITEM 10 - CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 7 of 7 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 12, 2002 - ----------------------------------------------------------------------- Date By: /s/ Robert L. Haunschild - ----------------------------------------------------------------------- Signature - The PNC Financial Services Group, Inc. Robert L. Haunschild, Senior Vice President and Chief Financial Officer - ----------------------------------------------------------------------- Name & Title February 12, 2002 - ----------------------------------------------------------------------- Date By: /s/ James B. Yahner - ----------------------------------------------------------------------- Signature - PNC Bancorp, Inc. James B. Yahner, Vice President - ------------------------------- Name & Title February 12, 2002 - ----------------------------------------------------------------------- Date By: /s/ Thomas R. Moore - ----------------------------------------------------------------------- Signature - PNC Bank, National Association Thomas R. Moore, Secretary - -------------------------- Name & Title February 12, 2002 - ----------------------------------------------------------------------- Date By: /s/ William J. Wykle - ----------------------------------------------------------------------- Signature - BlackRock Advisors, Inc. William J. Wykle, Managing Director - ----------------------------------- Name & Title February 12, 2002 - ----------------------------------------------------------------------- Date By: /s/ William J. Wykle - ----------------------------------------------------------------------- Signature - BlackRock Financial Management, Inc. William J. Wykle, Managing Director - ----------------------------------- Name & Title AN AGREEMENT TO FILE A JOINT STATEMENT WAS PREVIOUSLY FILED AS EXHIBIT A TO SCHEDULE 13G -----END PRIVACY-ENHANCED MESSAGE-----